header logo image header logo text
Downloads Login
Research
General Information
ZIRC
ZFIN ID: ZDB-FISH-150901-12102
Fish name: lama2teg15a/teg15a
Genotype: lama2teg15a/teg15a
Targeting Reagent: none
HUMAN DISEASE MODELED by lama2teg15a/teg15a
Human Disease Conditions Citations
muscular dystrophy control Li et al., 2015
congenital merosin-deficient muscular dystrophy 1A standard conditions (2)
GENE EXPRESSION
Gene expression in lama2teg15a/teg15a
Reporter gene expression No data available
PHENOTYPE
Phenotype in lama2teg15a/teg15a
Phenotype Conditions Figures
apoptotic process delayed, abnormal control Fig. 4 from Sztal et al., 2012
fast muscle cell detached from myoseptum, abnormal standard conditions Fig. 2 from Sztal et al., 2012
larval locomotory behavior decreased rate, abnormal standard conditions Table 1 from Granato et al., 1996
muscle damaged, abnormal standard conditions Fig. 1 from Sztal et al., 2012
muscle dystrophic, abnormal standard conditions Fig. 1 from Sztal et al., 2012
muscle refractivity, abnormal standard conditions Fig. 2 with image from Smith et al., 2017
muscle organ development disrupted, abnormal standard conditions Fig. 1 with imageFig. 3 with image from Hall et al., 2007
musculoskeletal movement decreased magnitude, abnormal standard conditions Fig. 1 with image from Smith et al., 2017
myotome degenerate, abnormal standard conditions Table 1 from Granato et al., 1996
myotome morphology, abnormal control Fig. 4 from Sztal et al., 2012
myotome refractivity, abnormal standard conditions Fig. 1Fig. 3Fig. 4 from Sztal et al., 2012
Table 1 from Granato et al., 1996
myotome structure, abnormal standard conditions Fig. 1 with imageFig. 3 with image from Hall et al., 2007
myotome extracellular matrix structure, abnormal standard conditions Fig. 4 with image from Hall et al., 2007
myotome sarcolemma structure, normal standard conditions Fig. 2 with image from Hall et al., 2007
myotome skeletal muscle cell decreased amount, abnormal standard conditions Fig. 1 with image from Jacoby et al., 2009
myotome skeletal muscle cell degeneration, abnormal standard conditions Fig. 1 with image from Jacoby et al., 2009
skeletal muscle decreased strength, abnormal chemical treatment: toluene-4-sulfonamide Fig. 4 with imageFig. 5 with image from Li et al., 2015
skeletal muscle decreased strength, abnormal control Fig. 4 with imageFig. 5 with image from Li et al., 2015
skeletal muscle deformed, abnormal chemical treatment: toluene-4-sulfonamide Fig. 2 with image from Li et al., 2015
skeletal muscle disorganized, abnormal control Fig. 2 with image from Li et al., 2015
skeletal muscle disorganized, abnormal chemical treatment: toluene-4-sulfonamide Fig. 5 with image from Li et al., 2015
skeletal muscle disorganized, ameliorated chemical treatment: toluene-4-sulfonamide Fig. 2 with image from Li et al., 2015
skeletal muscle structure, abnormal control Fig. 2 with imageFig. 3 with image from Li et al., 2015
skeletal muscle structure, ameliorated chemical treatment: toluene-4-sulfonamide Fig. 2 with imageFig. 3 with image from Li et al., 2015
skeletal muscle cell alignment skeletal muscle, abnormal chemical treatment: toluene-4-sulfonamide Fig. 2 with image from Li et al., 2015
skeletal muscle cell apoptotic, abnormal control Fig. 4 from Sztal et al., 2012
skeletal muscle cell detached from vertical myoseptum, abnormal standard conditions Fig. 1 with imageFig. 4 with image from Hall et al., 2007
skeletal muscle cell detached from myoseptum, abnormal standard conditions Fig. 1 from Sztal et al., 2012
skeletal muscle cell disorganized, abnormal control Fig. 2 with image from Li et al., 2015
skeletal muscle cell dystrophic, abnormal standard conditions Fig. 1 with image from Hall et al., 2007
skeletal muscle cell retracted, abnormal standard conditions Fig. 1 with imageFig. 4 with image from Hall et al., 2007
skeletal muscle cell undulate, abnormal chemical treatment: toluene-4-sulfonamide Fig. 2 with image from Li et al., 2015
skeletal muscle cell filamentous actin aggregated, abnormal standard conditions Fig. 5 with image from Smith et al., 2017
slow muscle cell detached from myoseptum, abnormal standard conditions Fig. 2Fig. 3Fig. 4 from Sztal et al., 2012
somite muscle cell detached from somite, abnormal standard conditions Fig. 2 with image from Smith et al., 2017
thigmotaxis decreased rate, abnormal standard conditions Table 1 from Granato et al., 1996
thigmotaxis disrupted, abnormal standard conditions Fig. 1 with image from Smith et al., 2017
trunk musculature degenerate, abnormal standard conditions Fig. 2 with image from Smith et al., 2017
vertical myoseptum deformed, abnormal standard conditions Fig. 5 with image from Hall et al., 2007
whole organism immobile, abnormal chemical treatment: toluene-4-sulfonamide text only from Li et al., 2015
whole organism neuromuscular junction structure, normal standard conditions Fig. 8 with image from Hall et al., 2007

CITATIONS  (8)